PROCEPT BioRobotics to Present at the 35ᵗʰ Annual Piper Sandler Healthcare Conference in New York City
13 Noviembre 2023 - 3:03PM
PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical
robotics company focused on advancing patient care by developing
transformative solutions in urology, today announced that members
of management will present at the upcoming 35th Annual Piper
Sandler Healthcare Conference in New York City. Management is
scheduled to present on Wednesday, November 29 at 1:30 p.m. Eastern
Time. A live webcast of the event, as well as an archived
recording, will be available on the “Investors” section of the
company’s website at: https://ir.procept-biorobotics.com. The
webcasts will be archived and available for replay for at least 90
days after the event.
About PROCEPT BioRobotics CorporationPROCEPT
BioRobotics is a surgical robotics company focused on advancing
patient care by developing transformative solutions in urology.
PROCEPT BioRobotics develops, manufactures and sells the AquaBeam
Robotic System, an advanced, image-guided, surgical robotic system
for use in minimally invasive urologic surgery with an initial
focus on treating benign prostatic hyperplasia, or BPH. BPH is the
most common prostate disease and impacts approximately 40 million
men in the United States. PROCEPT BioRobotics designed Aquablation
therapy to deliver effective, safe and durable outcomes for males
suffering from lower urinary tract symptoms, or LUTS, due to BPH
that are independent of prostate size and shape or surgeon
experience. The Company has developed a significant and growing
body of clinical evidence, which includes nine clinical studies and
over 150 peer-reviewed publications, supporting the benefits and
clinical advantages of Aquablation therapy.
Investor Contact:Matt BacsoVP, Investor
Relations and Business
Operationsm.bacso@procept-biorobotics.com
PROCEPT BioRobotics (NASDAQ:PRCT)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
PROCEPT BioRobotics (NASDAQ:PRCT)
Gráfica de Acción Histórica
De May 2023 a May 2024